[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_10763",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_10763"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00381"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "amlodipine besylate tablet usp is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension 1 1 o amlodipine besylate tablet usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions coronary artery disease 1 2 o chronic stable angina o vasospastic angina prinzmetal s or variant angina o angiographically documented coronary artery disease in patients without heart failure or an ejection fraction 4 amlodipine besylate tablet usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet usp control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy amlodipine besylate tablet usp may be used alone or in combination with other antihypertensive agents chronic stable angina amlodipine besylate tablet usp is indicated for the symptomatic treatment of chronic stable angina amlodipine besylate tablet usp may be used alone or in combination with other antianginal agents vasospastic angina prinzmetal s or variant angina amlodipine besylate tablet usp is indicated for the treatment of confirmed or suspected vasospastic angina amlodipine besylate tablet usp may be used as monotherapy or in combination with other antianginal agents angiographically documented cad in patients with recently documented cad by angiography and without heart failure or an ejection fraction 4 amlodipine besylate tablet usp is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00381",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-13T15:20:02.493+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "Ysn7Zw9cQ7a45V+SOyV/nYTKCqNZYBUK8OmFuinICfj/NcRrH+Y+SXgEBZc/p2+QZ8UlB9XT/pI1T8/G6wMr2JkS4pgcIYtMc68qELq2N6AdC8LvjHe+9JMMZxUv4PmY63lJYa75fqCw3AHsjTRSGNPEGrySeBcssZ3OtAoTdM8="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0"
    } ]
  } ],
  "@id" : "http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#pubinfo"
} ]